Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact
information

Dermatology

Wounds

O-linked N-acetylglucosamine (GlcNAc) transferase (OGT)

In vitro studies suggest blocking OGT activity could help treat diabetic skin wounds. In human keratinocytes cultured in hyperglycemic conditions, wound closure was delayed and general levels of O-GlcNAc addition to proteins was greater than that in cultures without excess glucose. In human keratinocytes cultured in hyperglycemic conditions, siRNA targeting OGT, the enzyme that adds O-GlcNAc to intracellular proteins, accelerated wound closure and decreased O-GlcNAc modifications compared with scrambled siRNA. Next steps include developing topical formulations of antisense oligonucleotides targeting OGT to treat diabetic wounds.

SciBX 7(5); doi:10.1038/scibx.2014.145
Published online Feb. 6, 2014

Patent application filed; available for licensing

Runager, K. et al. J. Biol. Chem.; published online Jan. 7, 2014;
doi:10.1074/jbc.M113.513952
Contact: David S. Rubenstein, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, N.C.
e-mail:
druben@med.unc.edu